Stephen Scoper, MD
Ophthalmology · Norfolk, VANPI 1871592352
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,950 of the $87,578 with a category attached, or 78.7%. Alcon accounts for 81.4% of it on its own, with 23 other manufacturers making up the rest. Reporting peaked in 2019 at $27,231 and has fallen 97.2% since, to $771 in 2025. Among ophthalmology clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 121 payments — averaging $723.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$71K
- Alcon Research LLC$14K
- AbbVie$445
- Amgen$287
- Tarsus Pharmaceuticals, Inc.$241
- Bausch & Lomb, A Division Of Bausch Health US, LLC$141
- plus $1K from 18 others
Across 2 payments — averaging $27,388 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$55K
What the payments were for
- Consulting fees$68,95079%
- Speaking & faculty fees$4,9006%
- Grants$3470%
- Travel & lodging$10,01511%
- Food & beverage$3,3524%
- Gifts$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 73 | $71,265 |
| Alcon Research LLC | 5 | $14,149 |
| AbbVie(2 entities) | 2 | $445 |
| Amgen(2 entities) | 8 | $287 |
| Tarsus Pharmaceuticals, Inc. | 2 | $241 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $141 |
| Lensar, Inc. | 2 | $130 |
| Mallinckrodt Hospital Products Inc. | 6 | $128 |
| Oyster Point Pharma, Inc. | 1 | $125 |
| Carl Zeiss Meditec, Inc. | 4 | $121 |
| Bausch & Lomb Americas Inc. | 1 | $112 |
| Omeros Corporation | 1 | $71 |
| Rayner Intraocular Lenses Limited | 2 | $63 |
| Carl Zeiss Meditec USA, Inc. | 1 | $60 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $36 |
| Apellis Pharmaceuticals, Inc. | 1 | $27 |
| Biotissue Holdings Inc. | 1 | $23 |
| ANI Pharmaceuticals, Inc. | 1 | $22 |
| Dompe US, Inc. | 1 | $22 |
| Ocular Therapeutix, Inc. | 1 | $20 |
| Sun Pharmaceutical Industries Inc. | 1 | $17 |
| Merz North America, Inc. | 1 | $15 |
| Harrow Eye, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORA$17,851
- AcrySof IQ VIVITY IOL$14,700
- AcrySof IQ PanOptix$13,397
- ARGOS$8,382
- Clareon$4,432
- Discovisc$2,975
- Verion$1,400
- Viscoat$525
- LUMIGAN$347
- XDEMVY$125
- TYRVAYA$125
- TEPEZZA$123
- ReSTOR$120
- ENVISTA ENVY$112
- LENSAR LASER SYSTEM$109
How this compares
$87,578 in reported general payments places this provider in the 95th percentile of 509 ophthalmology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 200 | $12,540 |
| Ketorolac Tromethamine | 194 | $7,218 |
| Loteprednol Etabonate | 14 | $2,030 |
| Fluorometholone | 15 | $1,762 |
| Tobramycin | 173 | $1,276 |
| Brimonidine Tartrate | 210 | $865 |
| Tropicamide | 18 | $176 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $141 | $2,03014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 509 ophthalmology providers in Virginia.
Other ophthalmology in Norfolk
- Elizabeth Yeu-LinNorfolk$1.7M
- John SheppardNorfolk$1.1M
- Constance OkekeNorfolk$800K
- Thomas JolyNorfolk$95K
- Kapil KapoorNorfolk$64K
- Albert CheungNorfolk$23K
- Samantha DewundaraNorfolk$19K
- Arielle SpitzeNorfolk$10K
- Rohit AdyanthayaNorfolk$6K
- Ethnie JonesRichmond$2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.